Brokerages expect Jounce Therapeutics, Inc. (NASDAQ:JNCE) to report $20.15 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Jounce Therapeutics’ earnings. The highest sales estimate is $20.29 million and the lowest is $20.00 million. The company is expected to issue its next earnings results on Tuesday, August 8th.

On average, analysts expect that Jounce Therapeutics will report full year sales of $20.15 million for the current year, with estimates ranging from $80.00 million to $81.16 million. For the next fiscal year, analysts expect that the firm will post sales of $130.05 million per share, with estimates ranging from $81.16 million to $206.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last released its earnings results on Tuesday, May 9th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.07. The company had revenue of $20.30 million for the quarter, compared to analysts’ expectations of $19.71 million. Jounce Therapeutics’s revenue was up 202900.0% on a year-over-year basis.

A number of equities analysts have recently commented on JNCE shares. Zacks Investment Research raised shares of Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a report on Wednesday, April 26th. Cowen and Company reaffirmed a “buy” rating on shares of Jounce Therapeutics in a report on Thursday, April 20th. Robert W. Baird started coverage on shares of Jounce Therapeutics in a report on Tuesday, February 21st. They issued an “outperform” rating and a $30.00 target price on the stock. Wells Fargo & Company started coverage on shares of Jounce Therapeutics in a report on Tuesday, February 21st. They issued an “outperform” rating on the stock. They noted that the move was a valuation call. Finally, J P Morgan Chase & Co started coverage on shares of Jounce Therapeutics in a report on Tuesday, February 21st. They issued an “overweight” rating and a $28.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Jounce Therapeutics has an average rating of “Buy” and a consensus price target of $28.67.

Shares of Jounce Therapeutics (JNCE) opened at 16.25 on Thursday. The stock’s market capitalization is $522.18 million. Jounce Therapeutics has a 12-month low of $15.50 and a 12-month high of $29.29. The stock has a 50 day moving average of $22.49 and a 200 day moving average of $21.98.

Institutional investors have recently bought and sold shares of the stock. Teachers Advisors LLC purchased a new position in Jounce Therapeutics during the first quarter worth $195,000. Paloma Partners Management Co purchased a new position in Jounce Therapeutics during the first quarter worth $212,000. TIAA CREF Investment Management LLC purchased a new position in Jounce Therapeutics during the first quarter worth $229,000. Goldman Sachs Group Inc. purchased a new position in Jounce Therapeutics during the first quarter worth $271,000. Finally, Morgan Stanley purchased a new position in Jounce Therapeutics during the first quarter worth $278,000. Hedge funds and other institutional investors own 39.35% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “$20.15 Million in Sales Expected for Jounce Therapeutics, Inc. (JNCE) This Quarter” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/06/15/20-15-million-in-sales-expected-for-jounce-therapeutics-inc-jnce-this-quarter-2.html.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient.

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.